uniQure (NASDAQ:QURE) Shares Gap Up – Time to Buy?

uniQure N.V. (NASDAQ:QURE) shares gapped up prior to trading on Friday . The stock had previously closed at $24.85, but opened at $28.75. uniQure shares last traded at $28.2020, with a volume of 1,190,591 shares changing hands.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. The Goldman Sachs Group upped their price objective on shares of uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, April 20th. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Chardan Capital upped their target price on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Finally, Wolfe Research started coverage on uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.83.

uniQure Trading Up 12.0%

The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average price is $19.91 and its two-hundred day moving average price is $21.87. The stock has a market capitalization of $1.76 billion, a P/E ratio of -8.00 and a beta of 0.87.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Equities research analysts forecast that uniQure N.V. will post -3.68 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 14,581 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $132,103.86. Following the completion of the transaction, the chief executive officer directly owned 660,658 shares in the company, valued at approximately $5,985,561.48. This represents a 2.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Walid Abi-Saab sold 45,000 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the transaction, the insider directly owned 169,669 shares of the company’s stock, valued at $4,251,905.14. This represents a 20.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 75,801 shares of company stock valued at $1,406,757 over the last quarter. Company insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp increased its holdings in shares of uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after purchasing an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC increased its stake in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares in the last quarter. Finally, MPM Bioimpact LLC acquired a new stake in uniQure during the fourth quarter worth about $33,062,000. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.